Analysts See $0.39 EPS for Hilltop Holdings Inc. (HTH); Cara Therapeutics, Inc. (CARA) Had 8 Bullish Analysts

December 29, 2017 - By Stephen Andrade

Among 9 analysts covering Cara Therapeutics (NASDAQ:CARA), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Cara Therapeutics had 21 analyst reports since July 27, 2015 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Friday, June 30. H.C. Wainwright maintained it with “Buy” rating and $3000 target in Friday, August 4 report. On Wednesday, June 21 the stock rating was maintained by Needham with “Buy”. The company was maintained on Thursday, July 13 by H.C. Wainwright. Canaccord Genuity maintained Cara Therapeutics, Inc. (NASDAQ:CARA) rating on Friday, August 4. Canaccord Genuity has “Buy” rating and $2500 target. On Friday, June 30 the stock rating was maintained by Laidlaw with “Buy”. On Friday, June 30 the stock rating was downgraded by Janney Capital to “Neutral”. The stock has “Buy” rating by Needham on Tuesday, October 3. The firm has “Buy” rating given on Friday, June 30 by Canaccord Genuity. The stock of Cara Therapeutics, Inc. (NASDAQ:CARA) has “Buy” rating given on Wednesday, June 21 by Stifel Nicolaus. See Cara Therapeutics, Inc. (NASDAQ:CARA) latest ratings:

03/10/2017 Broker: Needham Rating: Buy New Target: $23.0 Maintain
04/08/2017 Broker: Canaccord Genuity Rating: Buy New Target: $25.0000 Maintain
04/08/2017 Broker: Piper Jaffray Rating: Buy New Target: $27.0000 Maintain
03/08/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $20.0000 Maintain
04/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $30.0000 Maintain
13/07/2017 Broker: H.C. Wainwright Rating: Buy New Target: $30.0000 Maintain
30/06/2017 Broker: Canaccord Genuity Rating: Buy New Target: $25.0000 Maintain
30/06/2017 Broker: Laidlaw Rating: Buy New Target: $30.0000 Maintain
30/06/2017 Broker: H.C. Wainwright Rating: Buy New Target: $30.0000 Maintain
30/06/2017 Broker: Piper Jaffray Rating: Buy New Target: $27.0000

Analysts expect Hilltop Holdings Inc. (NYSE:HTH) to report $0.39 EPS on January, 25.They anticipate $0.03 EPS change or 8.33% from last quarter’s $0.36 EPS. HTH’s profit would be $37.40M giving it 16.29 P/E if the $0.39 EPS is correct. After having $0.31 EPS previously, Hilltop Holdings Inc.’s analysts see 25.81% EPS growth. The stock increased 0.91% or $0.23 during the last trading session, reaching $25.41. About 299,564 shares traded. Hilltop Holdings Inc. (NYSE:HTH) has risen 30.60% since December 29, 2016 and is uptrending. It has outperformed by 13.90% the S&P500.

Hilltop Holdings Inc. provides business and consumer banking services in Texas, California, Florida, Ohio, Washington, Arizona, Maryland, North Carolina, and other states. The company has market cap of $2.44 billion. The Company’s Banking segment offers savings, checking, interest-bearing checking, and money market accounts; certificates of deposit; lines and letters of credit, home improvement and equity loans, and loans for purchasing and carrying securities, equipment loans and leases, agricultural and commercial real estate loans, and other loans; and commercial, industrial, and single family residential mortgage loans. It has a 16.11 P/E ratio. This segment also provides term finance on commercial real estate properties; construction finance; treasury management; and check cards, safe deposit boxes, Internet banking, bill pay, overdraft, and automated teller machine services.

Since August 4, 2017, it had 0 insider purchases, and 3 selling transactions for $6.58 million activity. Another trade for 25,145 shares valued at $658,387 was sold by Martin John A. On Friday, August 4 the insider Feinberg Hill A sold $5.81 million. The insider GREEN J MARKHAM sold $114,016.

Among 7 analysts covering Hilltop Holdings (NYSE:HTH), 3 have Buy rating, 1 Sell and 3 Hold. Therefore 43% are positive. Hilltop Holdings had 20 analyst reports since August 4, 2015 according to SRatingsIntel. The stock of Hilltop Holdings Inc. (NYSE:HTH) earned “Buy” rating by Stephens on Friday, July 28. The rating was maintained by SunTrust with “Buy” on Sunday, October 29. The stock has “Mkt Perform” rating by FBR Capital on Monday, September 12. The rating was downgraded by Compass Point to “Neutral” on Wednesday, November 23. The firm has “Mkt Perform” rating given on Thursday, December 17 by Raymond James. The stock of Hilltop Holdings Inc. (NYSE:HTH) has “Overweight” rating given on Tuesday, August 4 by Piper Jaffray. On Tuesday, August 1 the stock rating was upgraded by Compass Point to “Buy”. The firm earned “Mkt Perform” rating on Friday, October 28 by FBR Capital. Keefe Bruyette & Woods maintained the stock with “Hold” rating in Thursday, December 21 report. The firm earned “Market Perform” rating on Thursday, March 31 by FBR Capital.

Investors sentiment increased to 1.13 in Q3 2017. Its up 0.21, from 0.92 in 2017Q2. It improved, as 16 investors sold Hilltop Holdings Inc. shares while 45 reduced holdings. 21 funds opened positions while 48 raised stakes. 52.43 million shares or 0.34% more from 52.25 million shares in 2017Q2 were reported. Guggenheim Ltd Liability Corporation owns 34,834 shares. Banc Funds Ltd Liability Corporation accumulated 227,532 shares. Goldman Sachs Gru has 379,512 shares for 0% of their portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) invested in 0% or 3,996 shares. Hsbc Hldg Public Ltd Com holds 0% or 9,520 shares. Cwm Limited Liability reported 0.03% stake. Dreman Value L L C holds 1,226 shares. Indexiq Ltd holds 0.04% in Hilltop Holdings Inc. (NYSE:HTH) or 31,551 shares. Qs, New York-based fund reported 157,074 shares. Cornercap Inv Counsel Incorporated reported 61,125 shares stake. California State Teachers Retirement Systems stated it has 0.01% in Hilltop Holdings Inc. (NYSE:HTH). Gsa Llp stated it has 45,871 shares. Moreover, Prelude Capital Mngmt Ltd Com has 0% invested in Hilltop Holdings Inc. (NYSE:HTH) for 700 shares. Credit Suisse Ag accumulated 80,190 shares. State Street invested in 0% or 1.96M shares.

The stock increased 0.31% or $0.04 during the last trading session, reaching $12.76. About 532,540 shares traded. Cara Therapeutics, Inc. (NASDAQ:CARA) has risen 206.00% since December 29, 2016 and is uptrending. It has outperformed by 189.30% the S&P500.

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. The company has market cap of $416.08 million. It is developing product candidates that target the body's peripheral nervous system. It currently has negative earnings. The companyÂ’s lead product candidate comprises I.V.

Investors sentiment decreased to 0.85 in Q3 2017. Its down 0.76, from 1.61 in 2017Q2. It is negative, as 22 investors sold Cara Therapeutics, Inc. shares while 31 reduced holdings. 20 funds opened positions while 25 raised stakes. 17.83 million shares or 4.68% less from 18.71 million shares in 2017Q2 were reported. Creative Planning reported 0% stake. Vantage Invest Advisors Limited Company holds 1,700 shares. 121,307 are held by Natl Bank Of New York Mellon Corp. Franklin Resources has 0% invested in Cara Therapeutics, Inc. (NASDAQ:CARA). Parametric Portfolio Associate Limited Company holds 0% or 33,521 shares. State Board Of Administration Of Florida Retirement Sys holds 0% of its portfolio in Cara Therapeutics, Inc. (NASDAQ:CARA) for 13,131 shares. 189,600 are held by Art Advisors Ltd Liability Co. Pnc Fin Service Grp invested 0% of its portfolio in Cara Therapeutics, Inc. (NASDAQ:CARA). Perigon Wealth Ltd Liability Corporation has invested 0% in Cara Therapeutics, Inc. (NASDAQ:CARA). Baker Avenue Asset Management Ltd Partnership has 34,221 shares for 0.05% of their portfolio. Commercial Bank Of America Corporation De owns 26,370 shares or 0% of their US portfolio. Kerrisdale Advisers Limited Liability Company holds 14,121 shares. Winslow Evans And Crocker Inc reported 0% in Cara Therapeutics, Inc. (NASDAQ:CARA). Jpmorgan Chase has 0% invested in Cara Therapeutics, Inc. (NASDAQ:CARA). State Of Wisconsin Board holds 20,000 shares or 0% of its portfolio.

Since August 4, 2017, it had 0 buys, and 1 sale for $45,000 activity. Menzaghi Frederique Ph.D. had sold 3,000 shares worth $45,000.